As part of Carleton University’s Science Café series, Michael Hildebrand of the Department of Neuroscience will present Chronic Pain: Uncovering a Path Towards Better Treatments.
When: Wednesday, Feb. 27, 2019 from 6:30 p.m. to 7:30 p.m.
Where: Sunnyside Branch of the Ottawa Public Library, 1049 Bank Street, Ottawa
Info: This event is free and open to the public.
Media are invited to attend the event.
Our inability to effectively and safely treat chronic pain is a major public health challenge. One in five Canadians experiences chronic pain, imposing huge personal and societal costs. The failure to develop new treatments may be partly due to the large divide between studies in animal pain models and the jump to testing specific therapeutics on humans.
In this presentation, Hildebrand will discuss “good” versus “bad” pain, how pain medicines work and the need to develop future therapeutics to block the “bad” forms of chronic pain. He will discuss his lab’s ongoing research into how dysfunctional signalling in the spinal cord drives chronic pain in both animal and human tissue models.
A unique collaboration with Ottawa Hospital neurosurgeon Eve Tsai is testing which pathological pain mechanisms are conserved across species – potentially shedding light on new therapeutic approaches to treat pain.
About Science Café
The Science Café series is organized by the Faculty of Science at Carleton to discuss relevant issues facing our society and how science can help solve real-world problems. Meet some of Carleton’s award-winning faculty members and graduate students as they share their excitement about science with the community. For more information, visit: Science.carleton.ca/science-cafe
Media Contact
Steven Reid
Media Relations Officer
Carleton University
613-520-2600, ext. 8718
613-265-6613
Steven_Reid3@Carleton.ca
Carleton Newsroom: https://newsroom.carleton.ca/
Follow us on Twitter: www.twitter.com/Cunewsroom
Need an expert? Go to: www.carleton.ca/newsroom/experts
Wednesday, February 20, 2019 in Media Advisories
Share: Twitter, Facebook
